HALOG® Ointment (Halcinonide, USP) 0.1%
Nonirritating, sustained relief for busy bodies with sensitive skin1-3
Patients suffering constant itch from eczema and atopic dermatitis need a treatment option that keeps up with their lifestyle.4
HALOG® Ointment provides continuous delivery of medication to the skin for quick effect and sustained relief.2
HALOG® Ointment acts quickly to reduce itch and prevent moisture loss2-4
HALOG® Ointment can be used safely on patients of all ages1:
— with no limits on weekly dose
— on large body surface areas
The active ingredient in HALOG® Ointment is halcinonide, 0.1%, the same as HALOG® Cream and HALOG® Solution.
Nonirritating HALOG® Ointment for sensitive skin1-3
Free of common ingredients that can irritate your skin1-3
- No preservatives
- No lanolin
- No propylene glycol
Creamy gel is easy to spread on dry, thick plaques, unlike other ointments2,3,5
• 0.1% halcinonide
• Nonirritating base*
*Base consists of mineral oil, polyethylene gel base, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 1450, and polyethylene glycol 6000 distearate with butylated hydroxytoluene.
Now available for scalp psoriasis!
Apply a thin layer to the affected area 2 to 3 times daily.1
Storing HALOG® Ointment
HALOG® Ointment should be stored at room temperature, do not place in excessive heat.1
References: 1. HALOG® Cream and Ointment [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2018. 2. Draelos ZD. A demonstration of the biphasic release characteristics of halcinonide 0.1% ointment. Poster presented at: 37th Annual Fall Clinical Dermatology Conference; October 18-21, 2018; Las Vegas, Nevada. 3. Greenberg RG, Fowler J Jr. Biphasic release halcinonide provides immediate and sustained class 2 topical corticosteroid activity. Poster presented at: Winter Clinical Dermatology Meeting; January 14-19, 2012; Lahaina, Hawaii. 4. Harrison IP, Spada F. Breaking the itch-scratch cycle: topical options for the management of chronic cutaneous itch in atopic dermatitis. Medicines (Basel). 2019;6(3):76. 5. Thau P, Fox C. A new procedure for the preparation of polyethylene-mineral oil gels. J Soc Cosmet Chem. 1965;16:359-363.
INDICATIONS AND USAGE
HALOG (Halcinonide OINTMENT, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
IMPORTANT SAFETY INFORMATION
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Application to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Use in Specific Populations
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Caution should be exercised when topical corticosteroids are administered to a nursing woman.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Please see Full Prescribing Information of respective products.
If you experience any Adverse Events you are encouraged to report them to the Drug Safety Department at 1-800-406-7984 or email Drug.Safety@ranbaxy.com. You can also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.